Predictors of Poor Prognosis in HFpEF
ConditionHFpEF
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation
About this trial
Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Signed and data informed consent;
New York Heart Association (NYHA) class II-III heart failure;
Left ventricular ejection fraction > 50%;
Elevated LV filling pressures assessed by echocardiography at rest or at peak exercise.
Disqualifiers
Evidence of myocardial ischemia during stress echocardiography;
Significant lesions of the main coronary arteries;
Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.);
Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion;
Trial population
Outpatients with HFpEF who underwent meticulous clinical evaluation between 2013 and 2020 at the National Medical Research Centre for Cardiology (Moscow, Russian Federation)
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
500 Participants
are grouped into 2 trial groupsGroup A: with primary outcome
Group B: without primary outcome
Trial outcomes
Primary outcomes
1
Hospitalization for exacerbation of HF
Time frame
From enrollment to August 20262
All-cause mortality
Time frame
From enrollment to August 2026Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov